IL-17/IL-17R blockade remarkability enhanced sensitivity to checkpoint blockade therapy, and the combination of IL-17 therapies and checkpoint blockade PD-1, CTLA4 offers a unique treatment option that may be effective in treating this lethal disease by triggering neutrophil extracellular traps and excluding cytotoxic CD8+ T cells from pancreatic tumors [90]. Here, IL17A is linked to pancreatic neoplasm.